Physician profile
Peter W Meier
NPI 1134742737
$679.22
in general payments reported to CMS, 2019-2025
12 companies · $255 in 2025
The $255 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $173 · 2024: $251 · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $679.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $140.81 | 2023-2025 | |
| Novo Nordisk INC | $123.54 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $102.62 | 2025 | |
| Amgen INC. | $90.44 | 2023-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $57.35 | 2024 | |
| Lilly USA, LLC | $56.78 | 2023 | Mounjaro, Trulicity |
| Philips North America LLC | $23.94 | 2025 | Vest Therapy Und |
| Idorsia Pharmaceuticals US INC | $19.70 | 2023 | Quviviq |
| Globus Medical, INC. | $18.71 | 2025 | Senza |
| Corcept Therapeutics | $16.03 | 2025 | Korlym |
| E.R. Squibb & Sons, L.L.C. | $15.84 | 2024 | Eliquis |
| Seqirus USA INC | $13.46 | 2025 | Fluad, Flucelvax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Meier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.